You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

~ Buy the PREVYMIS (letermovir) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PREVYMIS

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for PREVYMIS

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03728426 ↗	Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection	Recruiting	Merck Sharp & Dohme Corp.	Phase 2	2019-01-11	The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
NCT03728426 ↗	Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection	Recruiting	Amy C. Sherman, MD	Phase 2	2019-01-11	The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
NCT03728426 ↗	Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection	Recruiting	Dana-Farber Cancer Institute	Phase 2	2019-01-11	The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active cytomegalovirus infection or cytomegalovirus disease in patients with infections that are refractory or resistant to available treatments or who are experiencing organ dysfunction that makes unsafe the use of available antiviral treatments.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for PREVYMIS

Condition Name

Chart
Table

Condition Name for PREVYMIS
Intervention	Trials
Chronic Lymphocytic Leukemia	2
Hematopoietic and Lymphoid Cell Neoplasm	2
Hematopoietic Cell Transplant Recipient	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for PREVYMIS
Intervention	Trials
Neoplasms	2
Leukemia	2
Lymphoma	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for PREVYMIS

Trials by Country

Map
Table

Trials by Country for PREVYMIS
Location	Trials
United States	5
Canada	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for PREVYMIS
Location	Trials
California	2
Pennsylvania	1
Ohio	1
Massachusetts	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for PREVYMIS

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for PREVYMIS
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	5
N/A	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for PREVYMIS
Clinical Trial Phase	Trials
Not yet recruiting	4
Recruiting	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for PREVYMIS

Sponsor Name

Chart
Table

Sponsor Name for PREVYMIS
Sponsor	Trials
Merck Sharp & Dohme Corp.	4
National Cancer Institute (NCI)	2
Dana-Farber Cancer Institute	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for PREVYMIS
Sponsor	Trials
Other	7
Industry	4
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.